These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 30416772)

  • 1. Clinical predictors of pathologically response after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma: long term outcomes of a phase II study.
    Tan Z; Yang H; Wen J; Luo K; Liu Q; Hu Y; Zhang L; Liu M; Yun J; Fu J
    J Thorac Dis; 2018 Sep; 10(9):5254-5259. PubMed ID: 30416772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China.
    Zhang G; Zhang C; Sun N; Xue L; Yang Z; Fang L; Zhang Z; Luo Y; Gao S; Xue Q; Mu J; Gao Y; Tan F; He J
    J Cancer Res Clin Oncol; 2022 Apr; 148(4):943-954. PubMed ID: 34013382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nomogram for predicting pathologic complete response to neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.
    Liu G; Chen T; Zhang X; Hu B; Yu J
    Cancer Med; 2024 Mar; 13(5):e7075. PubMed ID: 38477511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diffusion-weighted MRI and
    Xu X; Sun ZY; Wu HW; Zhang CP; Hu B; Rong L; Chen HY; Xie HY; Wang YM; Lin HP; Bai YR; Ye Q; Ma XM
    Radiat Oncol; 2021 Jul; 16(1):132. PubMed ID: 34281566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the treatment outcomes of different neoadjuvant chemoradiotherapy regimens for resectable locally advanced esophageal cancer.
    Park H; Yang K; Noh JM; Shim YM; Kim HK; Choi YS; Cho JH; Sun JM; Jung HA; Park S; Park H; Oh D
    J Gastrointest Surg; 2024 Aug; ():. PubMed ID: 39127404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of pathological complete response to neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma.
    Huang RW; Chao YK; Wen YW; Chang HK; Tseng CK; Chan SC; Liu YH
    World J Surg Oncol; 2014 May; 12():170. PubMed ID: 24885430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
    Wang H; Tang H; Fang Y; Tan L; Yin J; Shen Y; Zeng Z; Zhu J; Hou Y; Du M; Jiao J; Jiang H; Gong L; Li Z; Liu J; Xie D; Li W; Lian C; Zhao Q; Chen C; Zheng B; Liao Y; Li K; Li H; Wu H; Dai L; Chen KN
    JAMA Surg; 2021 May; 156(5):444-451. PubMed ID: 33729467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Neoadjuvant Immunotherapy Plus Chemotherapy versus Neoadjuvant Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Study.
    Zhao J; Hao S; Tian J; Li Y; Han D
    J Inflamm Res; 2023; 16():3351-3363. PubMed ID: 37576156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moderately differentiated esophageal squamous cell carcinoma has a poor prognosis after neoadjuvant chemoradiotherapy.
    He W; Mao T; Yan J; Leng X; Deng X; Xie Q; Peng L; Liao Q; Scarpa M; Han Y
    Ann Transl Med; 2021 Apr; 9(8):706. PubMed ID: 33987404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant Therapy for Locally Advanced Esophageal Cancer Should Be Targeted to Tumor Histology.
    Stiles BM; Kamel MK; Harrison SW; Rahouma M; Lee B; Nasar A; Port JL; Altorki NK
    Ann Thorac Surg; 2019 Jan; 107(1):187-193. PubMed ID: 30278165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Impact of Postoperative Lymph Node Metastases After Neoadjuvant Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus: From the Results of NEOCRTEC5010, a Randomized Multicenter Study.
    Leng X; He W; Yang H; Chen Y; Zhu C; Fang W; Yu Z; Mao W; Xiang J; Chen Z; Yang H; Wang J; Pang Q; Zheng X; Liu H; Yang H; Li T; Zhang X; Li Q; Wang G; Mao T; Guo X; Lin T; Liu M; Fu J; Han Y
    Ann Surg; 2021 Dec; 274(6):e1022-e1029. PubMed ID: 31855875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of postoperative lymph node status on the prognosis of esophageal squamous cell carcinoma after esophagectomy following neoadjuvant chemoradiotherapy: a retrospective study.
    Sun Z; Xu X; Zhao X; Ma X; Ye Q
    J Gastrointest Oncol; 2021 Dec; 12(6):2685-2695. PubMed ID: 35070398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of circumferential resection margin in esophageal cancer with or without neoadjuvant chemoradiotherapy.
    Liu CY; Hsu PK; Hsu HS; Wu YC; Chuang CY; Lin CH; Hsu CP
    Dis Esophagus; 2020 Sep; 33(9):. PubMed ID: 32065226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study.
    Zhang X; Eyck BM; Yang Y; Liu J; Chao YK; Hou MM; Hung TM; Pang Q; Yu ZT; Jiang H; Law S; Wong I; Lam KO; van der Wilk BJ; van der Gaast A; Spaander MCW; Valkema R; Lagarde SM; Wijnhoven BPL; van Lanschot JJB; Li Z
    BMC Cancer; 2020 Mar; 20(1):194. PubMed ID: 32143580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa.
    Shapiro J; ten Kate FJ; van Hagen P; Biermann K; Wijnhoven BP; van Lanschot JJ
    Ann Surg; 2013 Nov; 258(5):678-88; discussion 688-9. PubMed ID: 24096766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Neoadjuvant Chemoradiotherapy on Pathological TNM Stage and Their Prognostic Significance for Surgically-treated Esophageal Squamous Cell Carcinoma.
    Hamai Y; Hihara J; Emi M; Furukawa T; Ibuki Y; Yamakita I; Kurokawa T; Okada M
    Anticancer Res; 2017 Oct; 37(10):5639-5646. PubMed ID: 28982881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and short-term outcomes of esophagectomy after neoadjuvant immunotherapy combined with chemotherapy or chemoradiotherapy for locally advanced esophageal squamous cell cancer: analysis of two phase-II clinical trials.
    Shen D; Chen R; Wu Q; Ji Y; van der Wilk BJ; Chen EY; Chen Q; Chen M
    J Gastrointest Oncol; 2024 Jun; 15(3):841-850. PubMed ID: 38989436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An International Cohort Study of Prognosis Associated With Pathologically Complete Response Following Neoadjuvant Chemotherapy Versus Chemoradiotherapy of Surgical Treated Esophageal Adenocarcinoma.
    Cools-Lartigue J; Markar S; Mueller C; Hofstetter W; Nilsson M; Ilonen I; Soderstrom H; Rasanen J; Gisbertz S; Hanna GB; Elliott J; Reynolds J; Kisiel A; Griffiths E; Van Berge Henegouwen M; Ferri L
    Ann Surg; 2022 Nov; 276(5):799-805. PubMed ID: 35861351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a nomogram for the prediction of pathological complete response after neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.
    Chao YK; Chang HK; Tseng CK; Liu YH; Wen YW
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27868287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemoglobin level influences tumor response and survival after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma.
    Hamai Y; Hihara J; Taomoto J; Yamakita I; Ibuki Y; Okada M
    World J Surg; 2014 Aug; 38(8):2046-51. PubMed ID: 24615604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.